Investment Rating - The report indicates a positive investment rating for the drug toxicology testing industry, highlighting its growth potential and increasing market demand [27]. Core Insights - The drug toxicology testing industry, also known as regulatory toxicology, is essential for evaluating the safety of chemical substances or products, particularly drugs. The industry is characterized by high barriers to entry in terms of certification and capital investment. The shift towards in vitro testing is expected to gradually replace in vivo testing in drug development, providing proactive guidance [4][8]. - The market size of China's drug toxicology testing industry has grown from 790 million yuan in 2018 to 1.41 billion yuan in 2022, with a compound annual growth rate (CAGR) of 15.8%. It is projected to reach 2.73 billion yuan by 2027, with a CAGR of 14.1% [27]. Industry Definition - Drug toxicology testing refers to the toxicological assessment of drugs, which is crucial for determining their safety and efficacy before clinical trials. This research spans all stages of drug development and is a key component of preclinical and clinical studies [4]. Industry Characteristics - The drug toxicology testing industry has high certification and capital investment barriers. It is a capital-intensive sector requiring significant initial investment in laboratory construction and testing equipment. Continuous funding is necessary for technological innovation and equipment maintenance [8][11]. Industry Development Stages - The drug toxicology testing industry has undergone three main development phases: 1. The embryonic phase (1780-1954), where foundational toxicological principles were established. 2. The initiation phase (1955-1984), marked by increased regulatory scrutiny following significant drug safety incidents. 3. The rapid development phase (1985-2023), characterized by the establishment of GLP standards and the standardization of toxicology testing [13][16]. Industry Chain Analysis - The upstream of the drug toxicology testing industry consists of raw material suppliers, while the midstream includes toxicology testing service providers. The downstream comprises drug manufacturers. The industry has a gross margin of approximately 30%, indicating strong profitability [17][23]. Market Trends - The demand for drug toxicology testing is expected to rise due to the increasing number of drug clinical trial registrations in China, which grew from 2,386 in 2019 to 3,410 in 2022. The robust investment in pharmaceutical R&D, which increased from 96.6 billion yuan in 2017 to 205.7 billion yuan in 2021, supports the growth of toxicology testing services [26][27]. Competitive Landscape - The drug toxicology testing industry in China is highly competitive, with a concentration of market share among leading firms. Companies like Huace Testing and Puni Testing dominate the market, benefiting from strong brand recognition and extensive experience [36][38].
药物毒理检测 头豹词条报告系列
Tou Bao Yan Jiu Yuan·2024-02-27 16:00